Desmoplastic/Nodular Medulloblastoma

Diseases /

Desmoplastic/Nodular Medulloblastoma

Back to Diseases List

Associated Genetic Biomarkers

APC
APC Loss
APC Mutation (germline)
BRCA2
BRCA2 Mutation (germline)
CDK6
CDK6 Amplification
CDK6 Mutation
CTNNB1
CTNNB1 Exon 3 Mutation (somatic)
CTNNB1 Expression
CTNNB1 Mutation
DDX3X
DDX3X Loss
DDX3X Mutation
GAB1 Expression
GAB1 No Expression
GFAP No Expression
GLI2
GLI2 Amplification

KDM6A
KDM6A Amplification
KDM6A Loss
KDM6A Mutation
KMT2C
KMT2C Amplification
KMT2C Loss
KMT2C Mutation
KMT2D
KMT2D Mutation

MAP2 Expression
MDM4
MDM4 Amplification
MKI67 Expression
MYCL
MYCL Amplification
MYCN
MYCN Amplification
MYCN Mutation
Monosomy 6

NGFR Expression
PALB2
PALB2 Mutation (germline)
PPM1D
PPM1D Amplification
PTCH1
PTCH1 Loss
PTCH1 Mutation (germline)
PTCH1 Mutation (somatic)
PTEN

PTEN Loss
RBFOX3 Expression
SFRP1 Expression
SHH
SHH Amplification
SMARCA4
SMARCA4 Loss
SMARCA4 Mutation
SMO
SMO Mutation (somatic)

SNCAIP
SNCAIP Amplification
SNCAIP Mutation
SUFU
SUFU Loss
SUFU Mutation (germline)
SUFU Mutation (somatic)
SYP Expression
TERT
TERT Promoter

TP53
TP53 Expression
TP53 Loss
TP53 Mutation (germline)
TP53 Mutation (somatic)
YAP1
YAP1 Amplification
YAP1 Expression
YAP1 No Expression
ZMYM3

ZMYM3 Amplification
ZMYM3 Loss
ZMYM3 Mutation
del(17)(p10)

Overview

NCI Definition: A medulloblastoma characterized by the presence of nodular, collagenous areas which do not contain reticulin, surrounded by hypercellular areas which contain an intercellular reticulin fiber network. [1]

Desmoplastic/nodular medulloblastomas most frequently harbor alterations in PTCH1, KMT2D, DDX3X, XPO1, and WRN [2].

Most Commonly Altered Genes in Desmoplastic/Nodular Medulloblastoma

PTCH1 Mutation, PTCH1 Missense, KMT2D Mutation, DDX3X Mutation, and WRN Mutation are the most common alterations in desmoplastic/nodular medulloblastoma [2].

Top Alterations in Desmoplastic/Nodular Medulloblastoma

Clinical Trials

View Clinical Trials for Desmoplastic/Nodular Medulloblastoma

There are 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are completed or closed. Of the trials that contain desmoplastic/nodular medulloblastoma as an inclusion criterion, 1 is phase 2 (1 open) and 1 is phase 4 (1 open).

APC, CDK6, and CTNNB1 are the most frequent gene inclusion criteria for desmoplastic/nodular medulloblastoma clinical trials [3].

Trials Investigating Desmoplastic/Nodular Medulloblastoma by Gene and Recruiting Status

Cisplatin, vincristine, and carboplatin are the most common interventions in desmoplastic/nodular medulloblastoma clinical trials.

Drugs Being Investigated in Desmoplastic/Nodular Medulloblastoma Trials by Recruiting Status

Significant Genes in Desmoplastic/Nodular Medulloblastoma

APC +

APC is altered in 5.26% of desmoplastic/nodular medulloblastoma patients [2].

APC is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

CDK6 +

CDK6 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

CTDNEP1 +

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [3].

CTNNB1 +

CTNNB1 is altered in 5.26% of desmoplastic/nodular medulloblastoma patients [2].

CTNNB1 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain CTNNB1 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

DDX3X +

DDX3X is altered in 23.08% of desmoplastic/nodular medulloblastoma patients [2].

DDX3X is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

GLI2 +

GLI2 is altered in 6.25% of desmoplastic/nodular medulloblastoma patients [2].

GLI2 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain GLI2 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

KDM6A +

KDM6A is altered in 6.25% of desmoplastic/nodular medulloblastoma patients [2].

KDM6A is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

KMT2C +

KMT2C is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2C status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

KMT2D +

KMT2D is altered in 25.0% of desmoplastic/nodular medulloblastoma patients [2].

KMT2D is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

LRP1B +

LRP1B is altered in 8.33% of desmoplastic/nodular medulloblastoma patients [2].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [3].

MDM4 +

MDM4 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [3].

MYCL +

MYCL is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCL status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

MYCN +

MYCN is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

OTX2 +

OTX2 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [3].

PPM1D +

PPM1D is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PPM1D status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

PTCH1 +

PTCH1 is altered in 37.5% of desmoplastic/nodular medulloblastoma patients [2].

PTCH1 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

PTEN +

PTEN is altered in 5.0% of desmoplastic/nodular medulloblastoma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

PVT1 +

PVT1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [3].

SHH +

SHH is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SHH status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

SMARCA4 +

SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

SMO +

SMO is altered in 10.53% of desmoplastic/nodular medulloblastoma patients [2].

SMO is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMO status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

SNCAIP +

SNCAIP is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SNCAIP status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

SUFU +

SUFU is altered in 12.5% of desmoplastic/nodular medulloblastoma patients [2].

SUFU is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SUFU status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

TERT +

TERT is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain TERT status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

TP53 +

TP53 is altered in 5.0% of desmoplastic/nodular medulloblastoma patients [2].

TP53 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

YAP1 +

YAP1 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain YAP1 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

ZMYM3 +

ZMYM3 is altered in 8.33% of desmoplastic/nodular medulloblastoma patients [2].

ZMYM3 is an inclusion eligibility criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain ZMYM3 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

Disease Details

Synonyms

Desmoplastic Medulloblastoma, Desmoplastic Nodular Medulloblastoma

Parent(s)

Medulloblastoma

OncoTree Name

Desmoplastic/Nodular Medulloblastoma

OncoTree Code

DMBL

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Desmoplastic/Nodular Medulloblastoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Desmoplastic/Nodular Medulloblastoma

Disease Details

References

About

Molecular Medicine

Content Types